Park Medi World Q1 FY27 Investor Presentation: PAT Jumps 35% as Hospital Network Expansion Accelerates

What Happened ?

Park Medi World Q1 FY27 Investor Presentation showcased another quarter of profitable growth supported by higher patient volumes, improved case mix and continued expansion of the hospital network.

Management emphasized the successful commissioning of new facilities, strategic acquisitions, brownfield expansions and a disciplined capital allocation strategy aimed at reaching 5,740 operational beds by FY28 while largely funding expansion through internal accruals and IPO proceeds.

key details

Strong Financial Performance:

• Revenue increased 19% YoY to ₹4,757 million.
• EBITDA grew 20% YoY.
• EBITDA margin remained healthy at 26.5%.
• PBT increased 28% YoY.
• PAT rose 35% YoY to ₹886 million.
• Net profit margin improved to 18.6%.

Note:

• Growth was driven by increasing patient volumes, improved ARPOB (Average Revenue Per Occupied Bed) and contributions from recently added hospitals.

Operating Performance:

• Operational bed capacity increased 32% YoY to 3,960 beds as of June 30, 2026.
• Total operational network currently comprises 17 hospitals with 4,290 beds.
• Patient volume increased 17% YoY.
• OPD patients reached 223,000.
• IPD patients increased to 26,000.
• Occupancy moderated to 55.6% due to significant capacity additions.

Note:

• Lower occupancy primarily reflects newly commissioned hospitals that are still ramping up operations. 

Expansion Strategy:

Management highlighted multiple ongoing expansion initiatives:

• Successfully commissioned 350-bed Panchkula Hospital.
• Commissioned 330-bed Medicity Hospital, Rudrapur.
• Approved 100-bed expansion at Palam Vihar (Park Platinum).
• Announced acquisition of 150-bed Mehar Hospital, Zirakpur.
• Narela (Delhi) hospital remains on schedule.
• Capacity expected to reach 4,740 beds by FY27-end.
• Long-term target of 5,740 beds by March 2028.

Note:

• Calendar year 2026 alone is expected to add approximately 1,490 beds, representing around 46% capacity expansion over the 2025 base. 

Acquisition-Led Growth:

• Successfully integrated 11 acquired hospitals.
• Total acquisition investment reached approximately ₹9,991 million.
• Acquisitions contributed:
  • 65% of revenue
  • 69% of EBITDA
  • 77% of PAT
• Average acquisition cost remains approximately ₹3.5 million per bed.

Note:

• Management continues to use acquisitions as a major growth driver while maintaining operational integration and profitability.

Clinical & Operational Excellence:

The company continues expanding high-acuity healthcare services through:

• 30+ super-speciality services.
• 1,166 ICU beds.
• 90+ operation theatres.
• 17 Cath Labs.
• 19 MRI machines.
• 17 CT scanners.
• 125 dialysis units.
• Advanced robotic surgery platforms across multiple hospitals.

Note:

• The growing share of super-speciality treatments is supporting higher revenue per occupied bed and improving profitability.

Financial Position & Growth Outlook:

Management highlighted:

• Negative net debt position.
• Approximately ₹2,998 million invested in fixed deposits.
• Strong liquidity supporting expansion.
• Future growth expected to be funded largely through:
  • Internal accruals.
  • IPO proceeds.
• No material fresh debt planned for current expansion pipeline.

Note:

• Strong balance sheet provides flexibility for future acquisitions and brownfield expansion. 

Industry Outlook:

Management expects continued structural growth supported by:

• Healthcare delivery market growing at 10–12% CAGR.
• Rising health insurance penetration.
• Expansion of Ayushman Bharat.
• Growing demand from Tier II and Tier III cities.
• Increasing medical tourism.
• Significant hospital bed shortage across North India.

Note:

• North India remains one of the most underpenetrated healthcare markets, providing long-term expansion opportunities.

Risk Analysis

Summary:

• Although Park Medi World continues to deliver strong earnings and execute its expansion strategy, future performance depends on successful integration of acquired hospitals, timely commissioning of projects and maintaining occupancy levels across new facilities.

Key Risks:

• Slower-than-expected ramp-up of newly commissioned hospitals.
• Integration risks from acquisitions.
• Higher operating costs during expansion.
• Doctor recruitment and retention challenges.
• Regulatory changes affecting healthcare reimbursement.
• Competitive intensity in North Indian healthcare markets.

Worst Case:

• If newly acquired hospitals require longer integration periods or occupancy recovery is slower than expected, margin expansion and earnings growth could moderate despite continued capacity additions.

Risk Level: Medium

Company Commentary

• Q1 FY27 focused on consolidation, growth and execution.
• Expansion pipeline across Uttarakhand, NCR and Punjab continues.
• Capacity expected to reach 5,740 beds by FY28.
• Expansion to be funded primarily through internal accruals and IPO proceeds.
• Focus remains on integrating acquired hospitals, improving utilisation and sustaining profitability.
• Long-term objective remains delivering affordable, high-quality healthcare while creating shareholder value.